Annual Report

Overview

The report highlights the company's rapid 2021 growth, with total operating income of RMB4,025 million and expanded drug pipelines. It describes global anti-pandemic work, including etesevimab and bamlanivimab authorization in more than 15 countries and regions. The ESG section reports 79,854.55 MWh of energy consumption and 35,535.04 tons of GHG emissions, alongside a group-wide workforce of 2,805 employees.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2021
Period: 1 January 2021 – 31 December 2021
Publication date: 31 March 2022
Language: English
Pages
File size

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services